<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02202187</url>
  </required_header>
  <id_info>
    <org_study_id>114595</org_study_id>
    <nct_id>NCT02202187</nct_id>
  </id_info>
  <brief_title>A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of&#xD;
      antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive&#xD;
      including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens&#xD;
      associated with respiratory tract, skin and soft tissue infections including isolates&#xD;
      resistant to existing classes of antimicrobials. This is a First Time in Human (FTIH) study&#xD;
      to assess the safety, tolerability, and pharmacokinetics of single oral doses of GSK2140944&#xD;
      in healthy volunteers. This study will be a single-blind, randomized, placebo-controlled,&#xD;
      dose-rising study in healthy subjects. The proposed single doses will range from 100 mg to&#xD;
      3000 mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of&#xD;
      antibiotics which is being developed for treatment of Gram positive [including methicillin&#xD;
      resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens associated with&#xD;
      respiratory tract and skin and soft tissue infections including isolates resistant to&#xD;
      existing classes of antimicrobials.&#xD;
&#xD;
      Study BTZ114595 will be the first administration of GSK2140944 in humans. This study will&#xD;
      examine the safety, tolerability, and pharmacokinetics of escalating single oral doses of&#xD;
      GSK2140944. The predicted clinical target for efficacy, based on preclinical efficacy models,&#xD;
      is an AUC(0-24) of 16-30 μg.h/mL. This study aims to explore the safety and tolerability at&#xD;
      and above target exposures in order to establish a therapeutic window for this compound.&#xD;
&#xD;
      This study will investigate the safety, tolerability, and pharmacokinetics of escalating&#xD;
      single oral doses of GSK2140944.&#xD;
&#xD;
      This will be a randomized, placebo-controlled, single-blind study to determine safety,&#xD;
      tolerability, and single dose pharmacokinetic (PK) profile of GSK2140944 in healthy subjects.&#xD;
&#xD;
      The projected single escalating doses of GSK2140944 will range from a starting dose of 100 mg&#xD;
      to a maximum dose of 3000 mg. The current plan is to administer the study drug after an&#xD;
      overnight fast, but based on emerging PK and safety data, it may be necessary to administer&#xD;
      the study drug under fed state to better understand safety, tolerability or PK of GSK2140944.&#xD;
      Any decision to remove or modify fasting requirements will be made by the GSK Study Team and&#xD;
      the investigator based on joint review of the emerging safety, tolerability and preliminary&#xD;
      pharmacokinetic data from prior dose-levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2011</start_date>
  <completion_date type="Actual">February 15, 2012</completion_date>
  <primary_completion_date type="Actual">February 15, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data assessed as change from baseline in 12-lead ECG</measure>
    <time_frame>Day 1, Day 2, Day 3 and at the Follow-up visit</time_frame>
    <description>12-lead ECGs will be obtained at each timepoint using an ECG machine, after the subject has rested in the supine position for at least 10 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data from dual-lead cardiac monitoring</measure>
    <time_frame>Day -1, Day 1</time_frame>
    <description>Continuous dual-lead cardiac monitoring will be obtained at each timepoints using an ECG machine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data assessed as change from baseline in clinical laboratory tests</measure>
    <time_frame>Day -1, Day 2, Day 3 and the Follow-up visit</time_frame>
    <description>Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data assessed as by number of adverse events (AE)</measure>
    <time_frame>Up to the Follow-up visit</time_frame>
    <description>Safety and tolerability parameters will include recording of AEs, throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data assessed as change from baseline in blood pressure</measure>
    <time_frame>Day -1, Day 1, Day 2, Day 3 and the Follow-up visit</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2140944 clinical safety data assessed as change from baseline in heart rate</measure>
    <time_frame>Day -1, Day 1, Day 2, Day 3 and the Follow-up visit</time_frame>
    <description>Vital sign measurements will include pulse rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: AUC(0-t) following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: AUC(0-infinity) following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Cmax following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include maximum observed concentration (Cmax) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: tmax following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include time of occurrence of Cmax (tmax) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: t1/2 following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include terminal phase half-life (t1/2) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess preliminary dose proportionality using PK parameter AUC(0-infinity) following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Preliminary dose proportionality will be assessed using PK parameter (AUC(0-infinity)) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess preliminary dose proportionality using PK parameter Cmax following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Preliminary dose proportionality will be assessed using PK parameter Cmax following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: (Ae) following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include urinary recovery of unchanged drug (Ae) following single dose of GSK2140944</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: (CLr) following single dose of GSK2140944</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>Pharmacokinetic data will include renal clearance (CLr) following single dose of GSK2140944</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Infections, Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>GSK2140944</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose range 100mg to 3000mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2140944</intervention_name>
    <description>Investigational Study Drug</description>
    <arm_group_label>GSK2140944</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male or female ranging from 18 to 60 years of age, at the time of signing the informed&#xD;
             consent. Female subject must be of non-childbearing potential defined as&#xD;
             pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40 MlU/ml and&#xD;
             estradiol &lt; 40 pg/mL (&lt;147 pmol/L) is confirmatory]. Females on hormone replacement&#xD;
             therapy (HRT) and whose menopausal status is in doubt will be required to use one of&#xD;
             the contraception methods in Section 8.1 if they wish to continue their HRT during the&#xD;
             study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal&#xD;
             status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will&#xD;
             elapse between the cessation of therapy and the blood draw; this interval depends on&#xD;
             the type and dosage of HRT. Following confirmation of their post-menopausal status,&#xD;
             they can resume use of HRT during the study without use of a contraceptive method.&#xD;
&#xD;
          -  Body weight ≥ 50 kg and BMI within the range 19 - 31 kg/m2, inclusive.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcF &lt; 450 msec, or QTc &lt; 480 msec in subjects with Bundle Branch Block., at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant central nervous system (e.g., seizures), cardiac,&#xD;
             pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such&#xD;
             conditions that, in the opinion of the investigator may place the subject at an&#xD;
             unacceptable risk as a participant in this trial or may interfere with the absorption,&#xD;
             distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          -  A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at&#xD;
             screening.&#xD;
&#xD;
          -  A screening urinalysis positive for protein or glucose (greater than &quot;trace&quot; findings&#xD;
             of protein or glucose).&#xD;
&#xD;
          -  Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B virus surface&#xD;
             antigen, or hepatitis C virus antibody at screening.&#xD;
&#xD;
          -  History of drug abuse within 6 months of the study.&#xD;
&#xD;
          -  History of smoking or use of nicotine containing products within 3 months of&#xD;
             screening, or a positive urine cotinine indicative of smoking at screening.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding an average weekly intake of greater&#xD;
             than or equal to 21 units for men/14 units for women or an average daily intake of&#xD;
             greater than or equal to 3 units for men/2 units for women. One unit is equivalent to&#xD;
             a 285 mL glass of full strength beer or 425 mL schooner of light beer or 1 (30 mL)&#xD;
             measure of spirits or 1 glass (100 mL) of wine.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received a drug or a new&#xD;
             chemical entity within 30 days or 5 half-lives, or twice the duration of the&#xD;
             biological effect of any drug (whichever is longer) prior to the first dose of current&#xD;
             study medication.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins above the&#xD;
             recommended daily intake (National Health and Medical Research Council in Australia&#xD;
             guideline), herbal and dietary supplements within 7 days or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, or use of St. John's Wort within&#xD;
             14 days prior to the first dose of study medication. By exception, the volunteer may&#xD;
             take paracetamol or acetaminophen (≤ 2 grams/day) or ibuprofen (1600 mg/day) up to 48&#xD;
             hours prior to the first dose of study medication. However, the investigator and study&#xD;
             team can review medication use on a case by case basis to determine if its use would&#xD;
             compromise subject safety or interfere with study procedures or data interpretation.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,&#xD;
             exotic citrus fruits or grapefruit hybrids or fruit juices containing such products&#xD;
             for 7 days prior to administration of study medication.&#xD;
&#xD;
          -  Donation of blood in excess of 550 mL within 12 weeks prior to dosing.&#xD;
&#xD;
          -  An unwillingness of male subjects to abstain from sexual intercourse with pregnant or&#xD;
             lactating women, or an unwillingness of male subjects to use a condom and spermicide,&#xD;
             in addition to having their female partner use another form of contraception such as&#xD;
             an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone,&#xD;
             subdermal implants or a tubal ligation, if engaging in sexual intercourse with a&#xD;
             female partner who could become pregnant. This criterion must be followed from the&#xD;
             time of study medication administration and until 84 days after study medication&#xD;
             administration.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical&#xD;
             research unit uses heparin to maintain intravenous cannula patency).&#xD;
&#xD;
          -  An unwillingness to comply with lifestyle and/or dietary restrictions as described in&#xD;
             Section 8.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gepotidacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02202187
org study id: 114595
nct id: NCT02202187
lead sponsor: 
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of
      antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive
      including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens
      associated with respiratory tract, skin and soft tissue infections including isolates
      resistant to existing classes of antimicrobials. This is a First Time in Human (FTIH) study
      to assess the safety, tolerability, and pharmacokinetics of single oral doses of GSK2140944
      in healthy volunteers. This study will be a single-blind, randomized, placebo-controlled,
      dose-rising study in healthy subjects. The proposed single doses will range from 100 mg to
      3000 mg.
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of
      antibiotics which is being developed for treatment of Gram positive [including methicillin
      resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens associated with
      respiratory tract and skin and soft tissue infections including isolates resistant to
      existing classes of antimicrobials.

      Study BTZ114595 will be the first administration of GSK2140944 in humans. This study will
      examine the safety, tolerability, and pharmacokinetics of escalating single oral doses of
      GSK2140944. The predicted clinical target for efficacy, based on preclinical efficacy models,
      is an AUC(0-24) of 16-30 μg.h/mL. This study aims to explore the safety and tolerability at
      and above target exposures in order to establish a therapeutic window for this compound.

      This study will investigate the safety, tolerability, and pharmacokinetics of escalating
      single oral doses of GSK2140944.

      This will be a randomized, placebo-controlled, single-blind study to determine safety,
      tolerability, and single dose pharmacokinetic (PK) profile of GSK2140944 in healthy subjects.

      The projected single escalating doses of GSK2140944 will range from a starting dose of 100 mg
      to a maximum dose of 3000 mg. The current plan is to administer the study drug after an
      overnight fast, but based on emerging PK and safety data, it may be necessary to administer
      the study drug under fed state to better understand safety, tolerability or PK of GSK2140944.
      Any decision to remove or modify fasting requirements will be made by the GSK Study Team and
      the investigator based on joint review of the emerging safety, tolerability and preliminary
      pharmacokinetic data from prior dose-levels.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: Single (Participant)
measure: GSK2140944 clinical safety data assessed as change from baseline in 12-lead ECG
time frame: Day 1, Day 2, Day 3 and at the Follow-up visit
description: 12-lead ECGs will be obtained at each timepoint using an ECG machine, after the subject has rested in the supine position for at least 10 minutes
measure: GSK2140944 clinical safety data from dual-lead cardiac monitoring
time frame: Day -1, Day 1
description: Continuous dual-lead cardiac monitoring will be obtained at each timepoints using an ECG machine
measure: GSK2140944 clinical safety data assessed as change from baseline in clinical laboratory tests
time frame: Day -1, Day 2, Day 3 and the Follow-up visit
description: Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters
measure: GSK2140944 clinical safety data assessed as by number of adverse events (AE)
time frame: Up to the Follow-up visit
description: Safety and tolerability parameters will include recording of AEs, throughout the study
measure: GSK2140944 clinical safety data assessed as change from baseline in blood pressure
time frame: Day -1, Day 1, Day 2, Day 3 and the Follow-up visit
description: Vital sign measurements will include systolic and diastolic blood pressure
measure: GSK2140944 clinical safety data assessed as change from baseline in heart rate
time frame: Day -1, Day 1, Day 2, Day 3 and the Follow-up visit
description: Vital sign measurements will include pulse rate
measure: Pharmacokinetic parameter: AUC(0-t) following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)) following single dose of GSK2140944
measure: Pharmacokinetic parameter: AUC(0-infinity) following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) following single dose of GSK2140944
measure: Pharmacokinetic parameter: Cmax following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include maximum observed concentration (Cmax) following single dose of GSK2140944
measure: Pharmacokinetic parameter: tmax following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include time of occurrence of Cmax (tmax) following single dose of GSK2140944
measure: Pharmacokinetic parameter: t1/2 following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include terminal phase half-life (t1/2) following single dose of GSK2140944
measure: To assess preliminary dose proportionality using PK parameter AUC(0-infinity) following single dose of GSK2140944
time frame: Up to Day 4
description: Preliminary dose proportionality will be assessed using PK parameter (AUC(0-infinity)) following single dose of GSK2140944
measure: To assess preliminary dose proportionality using PK parameter Cmax following single dose of GSK2140944
time frame: Up to Day 4
description: Preliminary dose proportionality will be assessed using PK parameter Cmax following single dose of GSK2140944
measure: Pharmacokinetic parameter: (Ae) following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include urinary recovery of unchanged drug (Ae) following single dose of GSK2140944
measure: Pharmacokinetic parameter: (CLr) following single dose of GSK2140944
time frame: Up to Day 4
description: Pharmacokinetic data will include renal clearance (CLr) following single dose of GSK2140944
arm group label: GSK2140944
arm group type: Experimental
description: Dose range 100mg to 3000mg single dose
arm group label: Matching Placebo
arm group type: Placebo Comparator
description: Placebo
intervention type: Drug
intervention name: GSK2140944
description: Investigational Study Drug
arm group label: GSK2140944
intervention type: Other
intervention name: Placebo
description: Placebo
arm group label: Matching Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United States
responsible party type: Sponsor
mesh term: Respiratory Tract Infections
mesh term: Gepotidacin